Drug intelligence / Profile preview

Wharton-Jelly mesenchymal stem cells

Development stage: Phase 2
Lead developer: Supergenics Life Science
Modality: Stem Cell Therapies → Cell Therapies
Administration: Peri-ulcer Injection

Overview

Wharton-Jelly mesenchymal stem cells are an allogeneic cell therapy derived from Wharton's Jelly, a gelatinous substance found in the umbilical cord. This investigational drug is being evaluated for its efficacy and safety in treating non-healing diabetic foot ulcers. The therapy is administered through peri-ulcer injections, aiming to promote complete ulcer healing and closure by leveraging the regenerative and immunomodulatory properties of these cells.

Other names: Allogeneic mesenchymal stem cells (MSCs)Allogeneic mesenchymal stromal cells (MSC)

Beyond the preview

Go deeper on Wharton-Jelly mesenchymal stem cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wharton-Jelly mesenchymal stem cells.

Explore the full profile